中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
10期
1289-1290
,共2页
慢性肾脏病%维生素D3%肿瘤坏死因子α
慢性腎髒病%維生素D3%腫瘤壞死因子α
만성신장병%유생소D3%종류배사인자α
Chronic kidney disease%Vitamin D3%Tumor necrosis factor-α
目的 探讨lα-羟基维生素D3[1α(OH)VitD3]对慢性肾脏病(CKD)5期患者微炎症状态的影响.方法 选择25例未进入透析治疗的CKD 5期患者作为试验组,20例健康志愿者为对照组.试验组口服1α(OH)VitD30.25 μg,2次/d；对照组不进行任何治疗.2组分别于试验组治疗前和治疗后2、4周检测血肿瘤坏死因子-α(TNF-α)浓度及SCr水平并进行比较分析.结果 试验组治疗前血TNF-α浓度为(97±21)μg/L,明显高于对照组[(57±12)μg/L,P＜0.01]；治疗2周后血TNF-α浓度为(66±10)μg/L,4周后血TNF-α浓度为(54±6)μg/L,与治疗前相比明显下降,差异有统计学意义(P＜0.01).试验组血SCr治疗前为(609±40)μmol/L,治疗2周后为(612±50)μmol/L,治疗4周后为(610 ±42)μmol/L,治疗前后相比差异无统计学意义(P＞0.05).结论 CKD时血液中TNF-α浓度增高.1α(OH)VitD3可以降低CKD 5期患者血液中TNF-α的水平,可能对CKD 5期患者微炎症状态具有调节作用.
目的 探討lα-羥基維生素D3[1α(OH)VitD3]對慢性腎髒病(CKD)5期患者微炎癥狀態的影響.方法 選擇25例未進入透析治療的CKD 5期患者作為試驗組,20例健康誌願者為對照組.試驗組口服1α(OH)VitD30.25 μg,2次/d；對照組不進行任何治療.2組分彆于試驗組治療前和治療後2、4週檢測血腫瘤壞死因子-α(TNF-α)濃度及SCr水平併進行比較分析.結果 試驗組治療前血TNF-α濃度為(97±21)μg/L,明顯高于對照組[(57±12)μg/L,P＜0.01]；治療2週後血TNF-α濃度為(66±10)μg/L,4週後血TNF-α濃度為(54±6)μg/L,與治療前相比明顯下降,差異有統計學意義(P＜0.01).試驗組血SCr治療前為(609±40)μmol/L,治療2週後為(612±50)μmol/L,治療4週後為(610 ±42)μmol/L,治療前後相比差異無統計學意義(P＞0.05).結論 CKD時血液中TNF-α濃度增高.1α(OH)VitD3可以降低CKD 5期患者血液中TNF-α的水平,可能對CKD 5期患者微炎癥狀態具有調節作用.
목적 탐토lα-간기유생소D3[1α(OH)VitD3]대만성신장병(CKD)5기환자미염증상태적영향.방법 선택25례미진입투석치료적CKD 5기환자작위시험조,20례건강지원자위대조조.시험조구복1α(OH)VitD30.25 μg,2차/d；대조조불진행임하치료.2조분별우시험조치료전화치료후2、4주검측혈종류배사인자-α(TNF-α)농도급SCr수평병진행비교분석.결과 시험조치료전혈TNF-α농도위(97±21)μg/L,명현고우대조조[(57±12)μg/L,P＜0.01]；치료2주후혈TNF-α농도위(66±10)μg/L,4주후혈TNF-α농도위(54±6)μg/L,여치료전상비명현하강,차이유통계학의의(P＜0.01).시험조혈SCr치료전위(609±40)μmol/L,치료2주후위(612±50)μmol/L,치료4주후위(610 ±42)μmol/L,치료전후상비차이무통계학의의(P＞0.05).결론 CKD시혈액중TNF-α농도증고.1α(OH)VitD3가이강저CKD 5기환자혈액중TNF-α적수평,가능대CKD 5기환자미염증상태구유조절작용.
Objective To investigate the effect of 1α(OH)VitD3 on the micro inflammatory state of chronic kidney disease patients.Methods Twenty five patients with chronic kidney disease(CKD)at stage 5 were divided to experimental group and 20 healthy people were divided to control group. 1α(OH)VitD3 was used in experimental group.The levels of tumor necrosis factor-α (TNF-α)and creatinine in serum were detected in the control group and experimental group before treatment,2 weeks and 4 weeks after treatment. Results The concentration of TNF-α in experimental group before treatment was higher than that in control group [(97 ± 21) μg/Lvs(57 ± 12)μg/L,P ＜0.01].The level of TNF-αα in experimental group significantly decreased after treatment for two-week and four-week [(66 ± 10)and(54 ± 6)μg/L,vs(97 ± 21)μg/L,P ＜ 0.01],while there was not difference between before and after treatment on concentration of Scr.Conclusion The concentration of serum TNF-α increase in patients with CKD at stage 5.1α(OH)VitD3 can decrease the level of serum TNF-α in patients with CKD at stage 5,which may provide an effect on micro inflammatory state of CKD patients.
